Latest Biotechnology News

Page 20 of 33
Prescient Therapeutics has extended its Share Purchase Plan closing date to 22 July 2025, aiming to raise up to A$7 million to advance its targeted cancer therapy PTX-100 through Phase 2 clinical trials.
Ada Torres
Ada Torres
15 July 2025
Alterity Therapeutics has responded to an ASX inquiry about its recent share price and volume spike, confirming no undisclosed information but highlighting imminent clinical data releases and investor roadshows as possible drivers.
Ada Torres
Ada Torres
14 July 2025
Nyrada has initiated the last cohort of its Phase I trial for Xolatryp, following a clean safety review of the highest dose tested so far. This step sets the stage for critical data that could shape the drug’s next development phase.
Ada Torres
Ada Torres
14 July 2025
Archer Materials advances its quantum computing and medical diagnostics technologies, extending key partnerships and forming a new advisory board while maintaining a strong cash position to fuel development.
Sophie Babbage
Sophie Babbage
14 July 2025
Bio-Gene Technology Limited has announced an offer of over 95 million Placement Options to investors and its Lead Manager, contingent on shareholder approval at an upcoming extraordinary general meeting. If exercised, these options could inject approximately $3.8 million into the company.
Ada Torres
Ada Torres
11 July 2025
Tissue Repair Limited has secured major distribution partnerships in Australia, New Zealand, and Thailand for its TR Pro+® product line, marking a pivotal shift from development to commercialisation. The company is also scaling up manufacturing and advancing regulatory approvals to support its global expansion ambitions.
Ada Torres
Ada Torres
11 July 2025
Invion Limited’s IVXO securities have been suspended from ASX quotation due to non-compliance with key listing rules, raising questions about the company’s regulatory standing and investor confidence.
Ada Torres
Ada Torres
11 July 2025
Imagion Biosystems has received encouraging feedback from the FDA on its planned Phase 2 HER2 breast cancer clinical trial, paving the way for its Investigational New Drug application submission later this year.
Ada Torres
Ada Torres
10 July 2025
Neurizon Therapeutics has received positive feedback from the FDA on its plan to resolve the clinical hold on its ALS drug candidate NUZ-001, with key preclinical studies completed ahead of schedule. The company aims to resume clinical trials in late 2025.
Ada Torres
Ada Torres
10 July 2025
Biome Australia Limited has confirmed its record FY25 sales revenue of approximately $18.4 million, marking a 41% increase year-on-year, while affirming full compliance with ASX continuous disclosure rules.
Ada Torres
Ada Torres
9 July 2025
PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its PYC-003 clinical trial and will soon begin dosing patients with Polycystic Kidney Disease, marking a pivotal step forward.
Ada Torres
Ada Torres
7 July 2025
BCAL Diagnostics has secured a strategic partnership with Cancer Care Associates to fast-track the clinical adoption and revenue generation of its innovative BREASTEST plus™ breast cancer blood test starting FY2026.
Ada Torres
Ada Torres
3 July 2025